Buy Soliris Eculizumab For Sale Online
SOLIRIS is used for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
• The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediatedthrombotic microangiopathy.
We can help patients in accessing/importing SOLIRIS, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.
Eculizumab (Soliris) is FDA-approved for the treatment of atypical hemolytic uremic syndrome (aHUS) in adult and pediatric patients to inhibit complement-mediated thrombotic microangiopathy (TMA) and also for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Eculizumab is not indicated for the treatment of patients with Shiga toxin E coli–related hemolytic uremic syndrome (STEC-HUS).1,2
Eculizumab is a monoclonal antibody that binds with high affinity to complement protein C5 and prevents the generation of the terminal complement complex C5b-9. In patients with PNH, eculizumab inhibits terminal complement–mediated intravascular hemolysis and in patients with aHUS, eculizumab inhibits complement-mediated TMA.1,2 Minimal eculizumab is excreted in urine with small quantities of immunoglobulin found in bile. The elimination half-life for PNH patients is 8 to 15 days and for aHUS patients, the elimination half-life is approximately 12 days.1,2
Dosing and Administration
Eculizumab dosing for adults with PNH is 600 mg IV every 7 days for the first 4 weeks, then 900 mg IV for the fifth dose 7 days later, then 900 mg every 14 days thereafter. Eculizumab dosing for adults with aHUS is 900 mg IV every 7 days for the first 4 weeks, then 1200 mg IV for the fifth dose 7 days later, then 1200 mg IV every 14 days thereafter. Pediatric dosing is based on body weight, with doses ranging from 300 mg to 900 mg.1,2 Eculizumab should be administered by IV infusion over 35 minutes via an infusion pump; it should not be administered as an IV push or bolus injection. Eculizumab should be diluted to a final concentration of 5 mg/mL by adding appropriate amounts of 0.9% sodium chloride (NaCl), 0.45% NaCl, 5% dextrose in water (D5W), or Ringer’s injection. The final infusion volume is 60 mL for 300-mg doses, 120 mL for 600-mg doses, 180 mL for 900-mg doses, and 240 mL for 1200-mg doses.1,2